Nasdaq AMZN Amazon
AWS Selected as Preferred Partner by Gilead Sciences
Biopharmaceutical company Gilead Sciences, Inc. (GILD) has selected Amazon Web Services, Inc. (AWS) as its preferred cloud partner. Meanwhile, shares of Amazon.com Inc. (AMZN), the parent company of AWS, closed up 1.6% at $3,561.57 on November 29.
New and Timely Medicine DeliveryAWS’s machine learning and analytics, together with its healthcare and life sciences experts and partners, will enable Gilead’s scientists to make data-driven decisions. These decisions will improve Gilead’s drug pipeline by giving insights across a series of data, from biomarker discovery through manufacturing and clinical trial recruitment.
AWS for Health provides easy accessibility that accelerates an organization’s innovation, unlocks the potential of health data, and develops personalized solutions for therapeutic care across 16 critical solution areas in healthcare, genomics, and biopharma.
With AWS onboard, Gilead’s research and development team will be able to strengthen their innovation and make informed decisions with valuable insights.
Gilead’s focus is on improving priority areas such as clinical program and study design, patient experience, and centralized statistical adaptive monitoring, which helps Gilead quickly identify and address potential issues related to the management of clinical trials.
AWS will also help in transforming Gilead’s workloads for its ERP project to implement SAP S/4HANA throughout the organization. The implementation will enhance important processes including supply chain, finance, operations, and commercial sales across all therapeutic areas and business units.
Furthermore, through the AWS cloud, Gilead will be able to shorten its hardware refresh cycles, increase testing and speed of delivery, and enable improved business planning. Similarly, Gilead will be able to run its ERP system more efficiently by using Amazon Elastic Compute Cloud (Amazon EC2) instance types.
Management CommentsSenior VP of Sales and Marketing at AWS, Matt Garman, said, “By streamlining their IT operations with AWS and taking advantage of our AWS for Health offerings, Gilead has the ability to continuously refine its approach to clinical trials, drug development, manufacturing, and distribution.”
Senior VP and Chief Information Officer at Gilead, Marc Berson, said, “With AWS as our preferred cloud provider, our researchers can use AWS’s portfolio of services to gain the insights, agility, and security needed to deliver new medicines at speed, and treat the individual according to their unique needs, not just the disease.”
See Analysts’ Top Stocks on TipRanks >>
Analysts’ TakeWith 31 unanimous Buys, the stock commands a Strong Buy consensus rating. The average Amazon.com price target of $4,095 implies 14.98% upside potential to current levels. Shares have gained 12.4% over the past year.
Website TrafficTipRanks’ Website Traffic tool, which uses data from SEMrush Holdings (SEMR), the world’s biggest website usage monitoring service, offers insight into AMZN's performance.
In October, Amazon website traffic recorded a 30.64% year-over-year decline in monthly visits. Similarly, year-to-date website traffic growth decreased 2.39% compared to the same period last year.
Related News:
Tesla Withdraws State Subsidy for Battery Plant in Berlin
Visa Concerned Over India’s Backing for Rival RuPay
Qiagen Reaffirms Effectiveness of PCR Tests on Omnicron Variant
US STOCKS-Wall Street rebounds after virus-related sell-off
US STOCKS-Wall Street rebounds after virus-related sell-off
Amazon Alabama facility ordered to re-run union election -U.S. labor board
U.S. FTC orders nine companies to provide information in supply chain probe
U.S. FTC orders nine companies to provide information in supply chain probe
US STOCKS-Wall Street regains some ground after virus pullback
US STOCKS-Tech rally lifts Wall Street from Omicron-driven rout
Why Amazon Is Rising Higher on Cyber Monday
CbdMD Gains On Exclusive Agreement With Amazon's Amify Platform
Cyber Monday spending expected to slow as shoppers see fewer deals
Could Cardano Hit $500 Billion by 2025?
MIDEAST STOCKS-Gulf bourses rebound as calm returns after Omicron battering
Do Bumble's Metaverse Ambitions Make Any Sense?
Cyber Monday sales expected to slow as shoppers see fewer deals
Amazon Setting Up Fulfillment Center in Abu Dhabi – Report
Amazon (AMZN) has inked a strategic partnership with Abu Dhabi Investment Office. Reuters reports that the two will establish a fulfillment center by 2024. The center is to be built in accordance with the tech giant’s carbon reduction strategies. AMZN shares fell 2.15% to close at $3,503.5 on November 26.
Amazon is a U.S. company that provides online retail shopping services and cloud computing services. The company operates through three business segments: North America, International, and Amazon Web Services.
Abu Dhabi Fulfillment CenterThe fulfillment center should create thousands of jobs while also enhancing Abu Dhabi’s logistics sector. Furthermore, it is expected to benefit the retail ecosystem at a time when e-commerce is growing at an impressive rate. The construction of the fulfillment center will also align with the United Arab Emirates UAE ambitions to achieve net-zero emissions by 2050. (See Top Smart Score Stocks on TipRanks)
Analyst RatingLast week, Guggenheim analyst Seth Sigman reiterated a Buy rating on Amazon with a $4,300 price target, implying 22.73% upside potential to current levels. The analyst remains bullish as the e-commerce giant enters fiscal 2022. He expects online channel share gains to reaccelerate early next year, after months of declines.
Sigman also expects normalizing consumer spending growth to be good for stocks. The analyst expects a significant positive inflection on Amazon in early 2022, compared to moderating sales and merging trends in the recent past.
Consensus RatingConsensus among analysts is a Strong Buy, based on 31 Buys. The average Amazon price target of $4,095 implies 16.88% upside potential to current levels.
Related News:
CP Rail-KCS Deal Gets Mexican Regulatory Approval
Analyzing Scotts Miracle-Gro’s Newly Added Risk Factor
Petrobras Hikes Investment Plan By 24% to $68B